Veeva Commercial Summit: Increased investment in medical affairs by pharma companies
Pharmaceutical companies are always looking to increase the efficiency of clinical trials, and now many of these companies are looking…
All articles by Phalguni Deswal
Phalguni Deswal
@Phalguni_GD
Phalguni Deswal is reporter in the healthcare and pharmaceutical sector. With a background in medicine, Phalguni has experience working in the Indian healthcare sector. Phalguni is interested in metabolic drug therapies, digital health technologies, and drug development.
-
-
Kronos mulls ‘strategic alternatives’ after axing cancer drug development
Kronos Bio has discontinued the development of its last remaining clinical asset, istisociclib (KB-0742), after a review of the safety…
-
Syros stock craters after lead cancer therapy flops in Phase III trial
Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial…
-
FDA delays priority review of Neurotech’s eye cell therapy implant
Neurotech Pharmaceuticals’ eye cell therapy implant has faced a setback as the US Food and Drug Administration (FDA) has extended…
-
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients…
-
DBV Technologies’ stock slides as financial woes worsens
DBV Technologies, which specialises in developing treatments for food allergies, has said that it will not have sufficient cash reserves…
-
Intra-Cellular bolsters Caplyta data with another Phase III win
Having raised the full-year sales guidance for Caplyta (lumateperone) a week ago, Intra-Cellular Therapeutics has reported positive topline data from…
-
NLS and Kadimastem stocks soar following merger agreement
Switzerland-based NLS Pharmaceutics and Israel-headquartered Kadimastem have signed a definitive merger agreement, with plans to form a joint biopharmaceutical aimed…
-
Lexicon stock tumbles after FDA AdCom votes against Zynquista again
The US Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (AdCom) has again voted against the approval…
-
Matinas BioPharma mulls wind-down as antifungal therapy deal falls through
Matinas BioPharma has halted all product development activities and fired 80% of its staff, including three members of senior management,…